• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

National Institute of Allergy and Infectious Disease Awards Grant to ResVita Bio


ResVita will use the money to develop a treatment for severe atopic dermatitis.

ResVita Bio announced that it has been awarded a $250,000 grant from the National Institute of Allergy and Infectious Disease (NIAID). The grant, titled the Phase 1 Small Business Innovation Research grant, will be used to develop a cell therapy for treating severe atopic dermatitis.

In a press release, ResVita Bio’s CEO Amin Zargar, PhD, said, “Within a year, we have been honored to receive two innovation grants from the NIH to develop therapies for both Netherton Syndrome, an orphan disease, and severe atopic dermatitis through our topical cell therapy approach. This is in addition to our Rare Pediatric Disease Designation for Netherton Syndrome from the FDA, setting the stage for the entry of our therapy into the clinic in 2025."

The treatment, called RVB-101, utilizes genetically engineered cells that are applied to the skin using a topical moisturizer. The cells then colonize the skin and repair the epidermal barrier and alleviate inflammation.


(September 18, 2023); PR Newswire; ResVita Bio Receives NIH Grant to Develop Breakthrough Treatment for Severe Atopic Dermatitis; https://www.prnewswire.com/news-releases/resvita-bio-receives-nih-grant-to-develop-breakthrough-treatment-for-severe-atopic-dermatitis-301929130.html

Related Videos
Related Content